These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 39306924)
1. Soluble PD-L1 shows no association to relapse and overall survival in early stage non-small cell lung cancer (NSCLC). Mildner FO; Sykora MM; Hackl H; Amann A; Zelger B; Sprung S; Buch ML; Nocera F; Moser P; Maier H; Augustin F; Manzl C; Kocher F; Pircher A; Lindenmann J; Mykoliuk I; Raftopoulou S; Kargl J; Wolf D; Sopper S; Gamerith G Lung Cancer; 2024 Oct; 196():107955. PubMed ID: 39306924 [TBL] [Abstract][Full Text] [Related]
2. Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients. He J; Pan Y; Guo Y; Li B; Tang Y J Immunother; 2020 Jun; 43(5):156-164. PubMed ID: 32168233 [TBL] [Abstract][Full Text] [Related]
3. The influence of plasma sPD-L1 concentration on the effectiveness of immunotherapy in advanced NSCLC patients. Chmielewska I; Grenda A; Krawczyk P; Frąk M; Kuźnar Kamińska B; Mitura W; Milanowski J Cancer Immunol Immunother; 2023 Dec; 72(12):4169-4177. PubMed ID: 37816808 [TBL] [Abstract][Full Text] [Related]
4. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related]
5. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
6. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer. Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759 [TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of soluble PD-L1 derived from tumor-associated macrophages in non-small-cell lung cancer. Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y Cancer Immunol Immunother; 2023 Nov; 72(11):3755-3764. PubMed ID: 37646826 [TBL] [Abstract][Full Text] [Related]
8. Biphasic prognostic significance of PD-L1 expression status in patients with early- and locally advanced-stage non-small cell lung cancer. Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y Cancer Immunol Immunother; 2021 Apr; 70(4):1063-1074. PubMed ID: 33113005 [TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596 [TBL] [Abstract][Full Text] [Related]
10. Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody. Murakami S; Shibaki R; Matsumoto Y; Yoshida T; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Ohe Y Thorac Cancer; 2020 Dec; 11(12):3585-3595. PubMed ID: 33108686 [TBL] [Abstract][Full Text] [Related]
11. Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer. Nagasaki Y; Taki T; Nomura K; Tane K; Miyoshi T; Samejima J; Aokage K; Ohtani-Kim SJ; Kojima M; Sakashita S; Sakamoto N; Ishikawa S; Suzuki K; Tsuboi M; Ishii G J Natl Cancer Inst; 2024 Jul; 116(7):1158-1168. PubMed ID: 38459590 [TBL] [Abstract][Full Text] [Related]
12. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990 [TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer. Qu Y; Wang H; Liu H; Sun X; Li J; Yu H Biomed Res Int; 2021; 2021():8811751. PubMed ID: 33987445 [TBL] [Abstract][Full Text] [Related]
14. Dynamic changes in PD-L1 expression and CD8 Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259 [TBL] [Abstract][Full Text] [Related]
15. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients. Li C; Li C; Zhi C; Liang W; Wang X; Chen X; Lv T; Shen Q; Song Y; Lin D; Liu H J Transl Med; 2019 Oct; 17(1):355. PubMed ID: 31665020 [TBL] [Abstract][Full Text] [Related]